Independent information services

Services

Quiet Harbor 64 offers carefully framed guides, comparisons, research summaries, and question-led tools for people trying to understand ibogaine and ketamine without turning uncertainty into a treatment recommendation.

Plain language, careful limits

Symbolic still life reflecting a careful side-by-side consideration of ibogaine and ketamine

Abstract arrangement suggesting the distinct contexts used to compare ibogaine and ketamine

A steadier starting point

Context before conclusions

Our starting point is a grounded comparison: what is being discussed, what has been studied, what remains uncertain, and where safety and regulation change the conversation. The main comparison overview provides a shared foundation before a reader moves into narrower questions.

Ibogaine and ketamine are not interchangeable topics. Their research histories, legal positioning, routes of use, and safety concerns differ. For example, the U.S. Drug Enforcement Administration lists ibogaine as a Schedule I controlled substance, while ketamine has approved medical uses under controlled conditions; those distinctions matter when reviewing federal drug scheduling information.

Quiet Harbor 64 is an independent resource, and the way we frame evidence and uncertainty is part of every guide. The aim is to support informed conversations, not to promote a treatment choice.

Information, not intervention

What these services cover

Each resource is designed to separate claims, questions, risks, and regulatory context into parts that can be examined without overstating what the evidence can say.

01 · Comparison guides

Side-by-side questions

Comparison guides organize differences in research, regulation, intended context, and reported risks. They also point readers toward focused material such as ibogaine HCl background information when terminology becomes a source of confusion.

02 · Research summaries

Evidence with boundaries

Research summaries distinguish early findings from established conclusions and note the limits of small studies, different populations, and changing legal contexts. The NCBI overview of ketamine is one useful reference for understanding why clinical use, pharmacology, and risk discussions should not be collapsed into one claim.

03 · Risk clarity

Safety-focused explainers

Safety explainers separate broad concerns from individual medical advice. Readers looking at recovery narratives can compare language around ibogaine aftereffects, while keeping in mind that personal accounts do not establish safety for any individual.

04 · Glossary and pathways

Terms, settings, and claims

Plain-language definitions help readers recognize what a claim is actually describing. This includes context around ibogaine detox centers, and why a setting or marketing term does not by itself resolve questions about screening, oversight, regulation, or risk.

The comparison bench

A decision framework made of questions

Rather than ranking substances or predicting outcomes, our framework asks readers to slow down around the details that often get skipped: the quality and limits of evidence, the legal setting, known safety concerns, and the difference between an information source and a provider.

Four parts to keep separate

What has been researched, and what has not
How law and regulation shape access and claims
Why individual health history changes risk discussions
Where promotional language exceeds available evidence

Readers exploring claims about mood may encounter pages about ibogaine for depression. Those claims should be weighed separately from the current status of research and from individualized clinical decision-making.

Likewise, discussion of ibogaine for addiction treatment should not obscure the serious medical safety questions associated with ibogaine. The background on ibogaine provides a general orientation to its history and legal classification, but it is not a substitute for professional medical or legal advice.

This question-led approach also applies to treatment-location claims. A mention of an ibogaine clinic in Tijuana or treatment centers in Mexico is context for evaluating information, not an endorsement, referral, or statement about quality or safety.

Provenance and limits

What careful comparison can—and cannot—do

These resources can clarify categories of information and identify questions worth bringing to an appropriately qualified professional. They cannot determine whether a substance, setting, or intervention is appropriate for a specific person.

For example, pages examining ibogaine treatment claims for Parkinson’s and whether ibogaine treatment works are best read as prompts to inspect the evidence, not as conclusions about a person’s condition or prospects.

Cost claims require the same restraint. Material about affordable ibogaine treatment may help identify the language being used, but affordability does not establish legitimacy, safety, evidence quality, or suitability.

Frequently asked questions

Useful boundaries for using these resources

Do these guides recommend a treatment?

No. Quiet Harbor 64 provides independent information and does not recommend, provide, or arrange treatment. The purpose is to make differences in evidence, risk, and regulation easier to identify.

Why compare regulation and safety separately from research?

They are distinct questions. A research finding does not establish legal status, and legal status does not resolve individual risk. Keeping the categories separate can make uncertainty easier to see.

Where should someone begin?

Begin with the side-by-side comparison, then use the safety and evidence pages to examine specific questions in more detail. If a situation involves personal health, medication, or legal concerns, seek advice from an appropriately qualified professional.

Keep the questions in view

Clarity begins with a careful comparison.

Explore the evidence-aware context behind ibogaine and ketamine while keeping safety, regulation, and uncertainty visible.

Explore evidence & guidance